Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of MF59-Adjuvanted Cell-Derived Quadrivalent Influenza Vaccine (aIIV4c) in Older Adults
NCT04576702Phase 2Completed
- Sponsor
- CSL Seqirus
- Start
- Oct 2020
- Primary completion
- Mar 2021
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of Influenza vaccine surface antigen adjuvanted with MF59 in influenza, sponsored by CSL Seqirus. Started Oct 2020; status: completed.
02
Drugs
Influenza vaccine surface antigen adjuvanted with MF59
03
Conditions
influenza
Beyond the preview
Go deeper on NCT04576702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04576702.